


INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/01296

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl. ⁷ : A61K 31/12, 31/352, 31/353, 31/555, 33/24, A61P 35/00, C07F 15/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN On-line Files MEDLINE, CA, WPIDS, BIOSIS Keywords# dehydroequol, platin?, cisplatin?, carboplatin?, isoflav?, genistein, daidzein, flavan?, flavon?, platin?, cisplat? STN Substructure Search		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN File Medline, abstract accession number 2001088116 & KHOSHYOMN S. et al., Pediatric Neurosurgery (2000 September), 33 (3), 123-31 "Synergistic action of genistein and cisplatin on growth inhibition and cytotoxicity of human medulloblastoma cells".	1-15
X	STN File Medline, abstract accession number 97367506 & CALTAGIRONE S. et. al., American Journal of Respiratory Cell and Molecular Biology, (1997 July) 17 (1) 51-9, "Interaction with type II estrogen binding sites and atiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer".	1-12, 14, 15
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search 27 October 2003		Date of mailing of the international search report - 7 NOV 2003
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929		Authorized officer  S.R. IDRUS Telephone No : (02) 6283 2659

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU03/01296

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	STN File Medline, abstract accession number 2003459262 & TAMURA S. et. al., Pigment Cell Research, (2003 Oct) 16 (5) 470-6 "Genistein enhances the cisplatin-induced inhibitions of cell growth and apoptosis in human malignant melanoma cells".	1-15
P, X	STN File Biosis, abstract accession number 2003:368481 & MANSOUR A. et. al., Blood (November 16, 2002) Vol.100, No. 11, pp. Abstract No. 4997 "Enhancement of chemotherapeutic efficacy by combining agents that block IL-10 in CIL cell lines"	1-15
X	STN File Medline, abstract accession number 2002151803 & S. GIACOMELLI et. al., Life Sciences (8 February 2002), 70(12), pages 1447-1459, "Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo in the activity of cisplatin".	16-19
X	STN File Medline, abstract accession number 2000404390 & CALTAGIRONE S. et. al., International Journal of Cancer (15 August 2000), 87(4), pages 595-600, "Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential".	16-19
X	STN File Medline, abstract accession number 96273517 & SCAMBIA G. et. al., European Journal of Cancer (May 1996), 32A(5), pages 877-882, "Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin".	16-19
X	STN File Medline, abstract accession number 91191699 & WAUD W. R. et. al., Cancer Chemotherapy and Pharmacology (1991), 27(6), pages 456-463, "Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia".	16-19
X	STN File Medline, abstract accession number 91107211 & NEELAM S. S. et. al., Investigational New Drugs (August 1990), 8(3), pages 263-268, "Combination of flavone acetic acid (FAA) with adriamycin, cisplatin and difluoromethylornithine (DFMO) in vitro against human colon cancer cells".	16-19
X	STN File Medline, abstract accession number 92032982 & SCAMBIA G. et. al., Anti-Cancer Drugs (October 1990), 1(1), pages 45-48, "Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth".	16-19
X	STN File CA, abstract number 119:131038 & DE VINCENZO R. et. al, Acta Medica Romana (1992), 30(1-2), pages 126-132, "Flavonoids and negative control of cell proliferation in ovarian tumors".	16-19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/01296

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ZYNER E. et. al., Acta Poloniae Pharmaceutica Drug Research, 1999, 56(2), pages 159-167, "Platinum (II) and palladium (II) N, O-chelates with substituted flavanone containing ligands". (see the whole document, in particular page 162, scheme 1 and page 164, table 1)	16-19
X	ZYNER E. et. al., Pharmazie, 1999, 54 (12), pages 945-946, "Pt(II) and Pd(II) complexes of 3-amino flavone: in vitro and in vivo evaluation". (see the whole document)	16-19
X	LEI W. et. al., Anticancer Research, 1999, volume 19, pages 221-228, "Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells". (see the whole document, in particular the abstract and page 224)	16-19
X	KANG B-J. et. al., Natural Product Sciences, 2000, 6(4), pages 165-169, "Scientific analysis of formulation theory of Chungpesagan-tang; in vitro cytotoxicity of cisplatin combined with Chungpesagan-tang". (see the whole document, in particular the abstract and page 168)	16-19
X	WO 02/02548 A1 (ORION CORPORATION) 10 January 2002 See pages 2 and 7 and claims	1-15
X	WO 00/66576 A1 (G.J. CONSULTANTS PTY LTD) 9 November 2000 See pages 4-7, 12-20, examples 1, 2, 6-11	1-15
X	WO 99/49862 A1 (THE UNIVERSITY OF MISSISSIPPI) 7 October 1999 See page 2 and claim 1	1-15
X	WO 98/17662 A1 (NOVARTIS AG) 30 April 1998 See pages 2-3, 9-11, 13, 16, 17, examples 5, 9(d) and claims	1-15
X	EP 267155 A2 (ZYMA SA) 11 May 1988 See pages 2-8, formulas (I), (IIa), (IIb), (IIc), examples and claims	1-15
X	WO 80/02098 A1 (Z-L LIMITED PARTNERSHIP) 16 October 1980 See pages 2-8, 12-16, 18 20-23, claims	1-15
X	SEPULVEDA-BOZA, S et al, "The Preparation of New Isoflavones", Synthetic Communications (2001) vol 31 no 12 pages 1933-1940 See page 1935 compound 4f, page 1931 paragraph 1	1-15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/01296

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	O'NEILL, M J et al, "Inducible Isoflavonoids from the Lima Bean, <i>Phaseolus lunatus</i> ", <i>Phytochemistry</i> (1986) vol 25 no 6 pages 1315-1322 See page 1316 column 1 compound 19 and column 2 paragraph 2	1-15
X	WOLFBEIS, O S et al, "The Absorption and Fluorescence of Isoflavones and the Effect of Shift Reagents", <i>Z. Naturforsch.</i> (1984) 39b pages 238-243 See page 240 Table 1 compounds 2, 8, 11, 13, 15, 18	1-15
X	ARORA, S K et al, "The Synthesis of Tlatlancuayin", <i>Tetrahedron</i> (1962) vol 18 pages 559-565 See page 559, page 560 compounds (V)-(VII) and paragraph 3, page 564 paragraphs 5 and 6, page 565	1-15
X	STN Chemical Abstract Accession No 135:355315 & Chemical And Pharmaceutical Bulletin (2001), 49 (9), 1229-1231	1-15
X	STN Chemical Abstract Accession No 135:121648 & Journal of Agricultural and Food Chemistry (2001), 49 (6) 3024-3033	1-15
X	STN Chemical Abstract Accession No 124:341448 & Archives of Microbiology (1995), 164 (6), 428-34	1-15
X	STN Chemical Abstract Accession No 124:316797 & Chemical And Pharmaceutical Bulletin (1996), 44 (3), 486-91	1-15
X	STN Chemical Abstract Accession No 124:140985 & Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (1995), 37 th , 493-8	1-15
X	STN Chemical Abstract Accession No 115:68424 & <i>Phytochemistry</i> (1991), 30 (4), 1281-4	1-15
X	STN Chemical Abstract Accession No 114:41246 & <i>Angewandte Botanik</i> (1990), 64 (1-2), 175-90	1-15
X	STN Chemical Abstract Accession No 112:69573 & <i>International Journal of Tissue Reactions</i> (1989), 11 (3), 107-12	1-15
X	STN Chemical Abstract Accession No 102:59329 & <i>Phytochemistry</i> (Elsevier) (1984), 23 (11), 2703-4	1-15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/01296

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN Chemical Abstract Accession No 102:59220 & Phytochemistry (Elsevier) (1984), 23 (6), 1342-3	1-15
X	STN Chemical Abstract Accession No 97:109739 & J. Chem. Soc., Perkin Trans. 1 (1982), (6), 1389-94	1-15
X	STN Chemical Abstract Accession No 95:111690 & Phytochemistry (1981), 20 (4), 799-801	1-15
X	STN Chemical Abstract Accession No 82:97918 & J. Inst. Chem., Calcutta (1974), 46, Pt. 3, 61-5	1-15
X	STN Chemical Abstract Accession No 76:140428 & J. Inst. Chem., Calcutta (1971), 43 (6), 234-40	1-15
X	STN Chemical Abstract Accession No 70:57577 Indian J. Chem. (1968), 6 (9), 481-4	1-15
X	STN Chemical Abstract Accession No 63:54537 & Bull. Chem. Soc. Japan (1965), 38 (6), 887-93	1-15
X	STN Chemical Abstract Accession No 61:61569 & Periodica Polytech. (1963), 7 (4), 241-58	1-15
X	STN Chemical Abstract Accession No 126:139728 (see CAS RN 116718-84-4) & Atherosclerosis (1997), 128(1), 59-66	1-15
X	JHA, H C et al, "Carbon-13 Chemical Shift Assignments of Chromones and Isoflavones", Can. J. Chem. (1980) vol 58 no 12 pages 1211-1219 See pages 1212-1213 Table 1(b) compounds 15, 17, 34-39, 41, 49-50	1-15
X	STN Chemical Abstracts Accession No 128:164027 & Antioxidants in Health and Disease (1998), 7 (Flavonoids in Health and Disease) pages 295-302	1-15
X	STN Chemical Abstracts Accession No 117:124019 & Biochemical Pharmacology (1992) vol 44(1), pages 157-162	1-15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU03/01296

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos : 1-15, 16-19
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
(i) as claims 1-15 are broadly drafted it is not economically possible to search the full scope of the claims. With due consideration to the examples, the search was limited to the isoflavones, and
(ii) claims 16-19 are directed to platinum-isoflavanoid complexes of formula (II), wherein the isoflavanoid ligand is as exemplified in the specification (compounds 1-30 on pages 19-22);
3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU03/01296

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
WO	9949862	AU	34564/99		
WO	9817662	AU	49479/97		
EP	267155	AU	80655/87	DD	275048
		FI	874804	HU	48611
		NO	874489	NZ	222411
		US	4814346	ZA	8708245
WO	8002098	US	4264509	BR	7909002
		DK	5288/80	EP	27796
		US	4366082	US	4366248
		US	4157984	US	4234577
		US	4218489	US	4232122
		DK	4928/80	EP	25783
		WO	8002027		
WO	0202548	AU	72597/01	FI	20001593
WO	0066576	EP	1189897		

END OF ANNEX

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 78273853	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/AU03/01296	International filing date (<i>day/month/year</i>) 2 October 2003	(Earliest) Priority Date (<i>day/month/year</i>) 2 October 2002
Applicant NOVOGEN RESEARCH PTY LTD et al		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of **8** sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (See Box II).

4. With regard to the title, ☒ the text is approved as submitted by the applicant.
☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract, ☒ the text is approved as submitted by the applicant
☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.
☐ as suggested by the applicant. ☒ None of the figures
☐ because the applicant failed to suggest a figure
☐ because this figure better characterizes the invention

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos : 1-15, 16-19
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
(i) as claims 1-15 are broadly drafted it is not economically possible to search the full scope of the claims. With due consideration to the examples, the search was limited to the isoflavones, and
(ii) claims 16-19 are directed to platinum-isoflavanoid complexes of formula (II), wherein the isoflavanoid ligand is as exemplified in the specification (compounds 1-30 on pages 19-22);
3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)


Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

A. CLASSIFICATION OF SUBJECT MATTER					
Int. Cl. ⁷ : A61K 31/12, 31/352, 31/353, 31/555, 33/24, A61P 35/00, C07F 15/00					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols)					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN On-line Files MEDLINE, CA, WPIDS, BIOSIS Keywords# dehydroequol, platin?, cisplatin?, carboplatin?, isoflav?, genistein, daidzein, flavan?, flavon?, platin?, cisplat? STN Substructure Search					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
X	STN File Medline, abstract accession number 2001088116 & KHOSHYOMN S. et al., Pediatric Neurosurgery (2000 September), 33 (3), 123-31 "Synergistic action of genistein and cisplatin on growth inhibition and cytotoxicity of human medulloblastoma cells".	1-15			
X	STN File Medline, abstract accession number 97367506 & CALTAGIRONE S. et. al., American Journal of Respiratory Cell and Molecular Biology, (1997 July) 17 (1) 51-9, "Interaction with type II estrogen binding sites and atiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer".	1-12, 14, 15			
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex					
<table style="width: 100%; border: none;"> <tr> <td style="width: 33%; vertical-align: top;"> * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 33%; vertical-align: top;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> <td style="width: 33%;"></td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family				
Date of the actual completion of the international search 27 October 2003		Date of mailing of the international search report - 7 NOV 2003			
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer  S.R. IDRUS Telephone No : (02) 6283 2659			

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	STN File Medline, abstract accession number 2003459262 & TAMURA S. et. al., Pigment Cell Research, (2003 Oct) 16 (5) 470-6 "Genistein enhances the cisplatin-induced inhibitions of cell growth and apoptosis in human malignant melanoma cells".	1-15
P, X	STN File Biosis, abstract accession number 2003:368481 & MANSOUR A. et. al., Blood (November 16, 2002) Vol.100, No. 11, pp. Abstract No. 4997 "Enhancement of chemotherapeutic efficacy by combining agents that block IL-10 in CIL cell lines"	1-15
X	STN File Medline, abstract accession number 2002151803 & S. GIACOMELLI et. al., Life Sciences (8 February 2002), 70(12), pages 1447-1459, "Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo in the activity of cisplatin".	16-19
X	STN File Medline, abstract accession number 2000404390 & CALTAGIRONE S. et. al., International Journal of Cancer (15 August 2000), 87(4), pages 595-600, "Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential".	16-19
X	STN File Medline, abstract accession number 96273517 & SCAMBIA G. et. al., European Journal of Cancer (May 1996), 32A(5), pages 877-882, "Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin".	16-19
X	STN File Medline, abstract accession number 91191699 & WAUD W. R. et. al., Cancer Chemotherapy and Pharmacology (1991), 27(6), pages 456-463, "Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia".	16-19
X	STN File Medline, abstract accession number 91107211 & NEELAM S. S. et. al., Investigational New Drugs (August 1990), 8(3), pages 263-268, "Combination of flavone acetic acid (FAA) with adriamycin, cisplatin and difluoromethylornithine (DFMO) in vitro against human colon cancer cells".	16-19
X	STN File Medline, abstract accession number 92032982 & SCAMBIA G. et. al., Anti-Cancer Drugs (October 1990), 1(1), pages 45-48, "Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth".	16-19
X	STN File CA, abstract number 119:131038 & DE VINCENZO R. et. al, Acta Medica Romana (1992), 30(1-2), pages 126-132, "Flavonoids and negative control of cell proliferation in ovarian tumors".	16-19

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ZYNER E. et. al., Acta Poloniae Pharmaceutica Drug Research, 1999, 56(2), pages 159-167, "Platinum (II) and palladium (II) N, O-chelates with substituted flavanone containing ligands". (see the whole document, in particular page 162, scheme 1 and page 164, table 1)	16-19
X	ZYNER E. et. al., Pharmazie, 1999, 54 (12), pages 945-946, "Pt(II) and Pd(II) complexes of 3-aminoflavone: in vitro and in vivo evaluation". (see the whole document)	16-19
X	LEI W. et. al., Anticancer Research, 1999, volume 19, pages 221-228, "Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells". (see the whole document, in particular the abstract and page 224)	16-19
X	KANG B-J. et. al., Natural Product Sciences, 2000, 6(4), pages 165-169, "Scientific analysis of formulation theory of Chungpesagan-tang; in vitro cytotoxicity of cisplatin combined with Chungpesagan-tang". (see the whole document, in particular the abstract and page 168)	16-19
X	WO 02/02548 A1 (ORION CORPORATION) 10 January 2002 See pages 2 and 7 and claims	1-15
X	WO 00/66576 A1 (G.J. CONSULTANTS PTY LTD) 9 November 2000 See pages 4-7, 12-20, examples 1, 2, 6-11	1-15
X	WO 99/49862 A1 (THE UNIVERSITY OF MISSISSIPPI) 7 October 1999 See page 2 and claim 1	1-15
X	WO 98/17662 A1 (NOVARTIS AG) 30 April 1998 See pages 2-3, 9-11, 13, 16, 17, examples 5, 9(d) and claims	1-15
X	EP 267155 A2 (ZYMA SA) 11 May 1988 See pages 2-8, formulas (I), (IIa), (IIb), (IIc), examples and claims	1-15
X	WO 80/02098 A1 (Z-L LIMITED PARTNERSHIP) 16 October 1980 See pages 2-8, 12-16, 18 20-23, claims	1-15
X	SEPULVEDA-BOZA, S et al, "The Preparation of New Isoflavones", Synthetic Communications (2001) vol 31 no 12 pages 1933-1940 See page 1935 compound 4f, page 1931 paragraph 1	1-15

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	O'NEILL, M J et al, "Inducible Isoflavonoids from the Lima Bean, Phaseolus lunatus", Phytochemistry (1986) vol 25 no 6 pages 1315-1322 See page 1316 column 1 compound 19 and column 2 paragraph 2	1-15
X	WOLFBEIS, O S et al, "The Absorption and Fluorescence of Isoflavones and the Effect of Shift Reagents", Z. Naturforsch. (1984) 39b pages 238-243 See page 240 Table 1 compounds 2, 8, 11, 13, 15, 18	1-15
X	ARORA, S K et al, "The Synthesis of Tlatlancuayin", Tetrahedron (1962) vol 18 pages 559-565 See page 559, page 560 compounds (V)-(VII) and paragraph 3, page 564 paragraphs 5 and 6, page 565	1-15
X	STN Chemical Abstract Accession No 135:355315 & Chemical And Pharmaceutical Bulletin (2001), 49 (9), 1229-1231	1-15
X	STN Chemical Abstract Accession No 135:121648 & Journal of Agricultural and Food Chemistry (2001), 49 (6) 3024-3033	1-15
X	STN Chemical Abstract Accession No 124:341448 & Archives of Microbiology (1995), 164 (6), 428-34	1-15
X	STN Chemical Abstract Accession No 124:316797 & Chemical And Pharmaceutical Bulletin (1996), 44 (3), 486-91	1-15
X	STN Chemical Abstract Accession No 124:140985 & Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (1995), 37 th , 493-8	1-15
X	STN Chemical Abstract Accession No 115:68424 & Phytochemistry (1991), 30 (4), 1281-4	1-15
X	STN Chemical Abstract Accession No 114:41246 & Angewandte Botanik (1990), 64 (1-2), 175-90	1-15
X	STN Chemical Abstract Accession No 112:69573 & International Journal of Tissue Reactions (1989), 11 (3), 107-12	1-15
X	STN Chemical Abstract Accession No 102:59329 & Phytochemistry (Elsevier) (1984), 23 (11), 2703-4	1-15

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN Chemical Abstract Accession No 102:59220 & Phytochemistry (Elsevier) (1984), 23 (6), 1342-3	1-15
X	STN Chemical Abstract Accession No 97:109739 & J. Chem. Soc., Perkin Trans. 1 (1982), (6), 1389-94	1-15
X	STN Chemical Abstract Accession No 95:111690 & Phytochemistry (1981), 20 (4), 799-801	1-15
X	STN Chemical Abstract Accession No 82:97918 & J. Inst. Chem., Calcutta (1974), 46, Pt. 3, 61-5	1-15
X	STN Chemical Abstract Accession No 76:140428 & J. Inst. Chem., Calcutta (1971), 43 (6), 234-40	1-15
X	STN Chemical Abstract Accession No 70:57577 Indian J. Chem. (1968), 6 (9), 481-4	1-15
X	STN Chemical Abstract Accession No 63:54537 & Bull. Chem. Soc. Japan (1965), 38 (6), 887-93	1-15
X	STN Chemical Abstract Accession No 61:61569 & Periodica Polytech. (1963), 7 (4), 241-58	1-15
X	STN Chemical Abstract Accession No 126:139728 (see CAS RN 116718-84-4) & Atherosclerosis (1997), 128(1), 59-66	1-15
X	JHA, H C et al, "Carbon-13 Chemical Shift Assignments of Chromones and Isoflavones", Can. J. Chem. (1980) vol 58 no 12 pages 1211-1219 See pages 1212-1213 Table 1(b) compounds 15, 17, 34-39, 41, 49-50	1-15
X	STN Chemical Abstracts Accession No 128:164027 & Antioxidants in Health and Disease (1998), 7 (Flavonoids in Health and Disease) pages 295-302	1-15
X	STN Chemical Abstracts Accession No 117:124019 & Biochemical Pharmacology (1992) vol 44(1), pages 157-162	1-15

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU03/01296

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
WO	9949862	AU	34564/99		
WO	9817662	AU	49479/97		
EP	267155	AU	80655/87	DD	275048
		FI	874804	HU	48611
		NO	874489	NZ	222411
		US	4814346	ZA	8708245
WO	8002098	US	4264509	BR	7909002
		DK	5288/80	EP	27796
		US	4366082	US	4366248
		US	4157984	US	4234577
		US	4218489	US	4232122
		DK	4928/80	EP	25783
		WO	8002027		
WO	0202548	AU	72597/01	FI	20001593
WO	0066576	EP	1189897		

END OF ANNEX